Does K-11706 Enhance Performance and Why?

Abstract

Erythropoietin gene expression is stimulated by hypoxia-inducible factor 1 and inhibited by GATA. Thus, drugs that attenuate the action of GATA and/or potentiate the action of HIF-1 may increase Epo production and hemoglobin concentration. The effects of such drugs on endurance performance and the potential mechanisms by which they may exert effects are unclear. In Hep3B cells, we showed that K-11706 inhibits GATA binding activity, but enhances HIF-1 binding activity. However, the expression levels of GATA and HIF-1 protein were not changed by the addition of K-11706. We investigated the effects of K-11706 on Epo and Hb concentrations, hematocrit and endurance performance of mice (total number of mice = 40). K-11706 was dissolved in polyethylene glycol and administered via oral tube feeding to mice for either five or eight days. Endurance performance was assessed using a treadmill. Muscle fibers from the quadriceps muscles of mice were stained with ATPase. Administration of 3 mg/kg K-11706 for five or eight days significantly increased erythropoietin concentrations, hemoglobin concentrations, hematocrit and endurance performance, but the diameters of cross-sections and ratios of type I, IIA and IIB muscle fibers were not affected.

Key words

transcription factors - erythropoietin - treadmill

References

• 1 Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M T, Marion B, Bressolle F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.  Med Sci Sports Exerc. 1999;  31 639-645
• 2 Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men.  J Intern Med. 1991;  229 125-130
• 3 Birkeland K I, Stray-Gundersen J, Hemmersbach P, Hallen J, Hang E, Bahr R. Effect of rhEpo administration on serum level of sTfR and cycling performance.  Med Sci Sports Exerc. 2000;  32 1238-1243
• 4 Brugnara C, Colella G M, Cremins J, Langley Jr R C, Schneider T J, Rutherford C J, Goldberg M A. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis.  J Lab Clin Med. 1994;  123 660-667
• 5 Buick F J, Gledhill N, Froese A B, Spriet L, Meyers E C. Effect of induced erythrocythemia on aerobic work capacity.  J Appl Physiol. 1980;  48 636-642
• 6 Ekblom B, Goldbarg A N, Gullbring B. Response to exercise after blood loss and reinfusion.  J Appl Physiol. 1972;  33 175-180
• 7 Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power.  Scand J Med Sci Sports. 1991;  1 88-93
• 8 Ekblom B. Blood doping and erythropoietin: the effects of variation in hemoglobin concentration and other related factors on physical performance.  Am J Sports Med. 1996;  24 S40-S42
• 9 Hoshino S, Ohkoshi N, Ishii A, Kameya S, Takeda S, Shoji S. The expression of dystrophin and α 1-syntrophin during skeletal muscle regeneration.  J Muscle Res Cell Motil. 2001;  22 185-191
• 10 Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors.  Blood. 1997;  89 1430-1439
• 11 Jaakkola P, Mole D R, Tian Y M, Wilson M I, Gielbert J, Gaskell S J, Kriegsheim A V, Hebestreit H F, Mukherji M, Schofield C J, Maxwell P H, Pugh C W, Ratcliffe P J. Targeting of HIF-1α to the von Hippel-Lindau ubiquitylation complex by O₂-regulated proryl hydroxylation.  Science. 2001;  292 468-472
• 12 Joyner M J. V·O_2max blood doping and erythropoietin.  Br J Sports Med. 2003;  37 190-191
• 13 Lappin T R, Maxwell A P, Johnston P G. EPO's alter ego: Erythropoietin has multiple actions.  Stem Cells. 2002;  20 485-492
• 14 Lundby C, Gassmann M, Pilegaard H. Regular enhance training reduces the training induced HIF-1α and HIF-2α mRNA expression in human skeletal muscles in normoxic conditions.  Eur J Appl Physiol. 2005;  12 1-7
• 15 Maxwell P H, Wiesener M S, Chang G W, Clifford S C, Vaux E C, Cockman M E, Wykoff C C, Pugh C W, Maher E R, Ratcliffe P J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.  Nature. 1999;  399 271-275
• 16 Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease.  Blood. 2004;  104 4300-4307
• 17 Ogilvie M, Yu X, Nicolas-Metral V, Pulido S M, Liu C, Ruegg U T, Noguchi C T. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts.  J Biol Chem. 2000;  375 39754-39761
• 18 Parisotto R, Wu M, Ashenden M J, Emslie K R, Gore C J, Howe C, Kazlauskas R, Sharpe K, Trout G J, Xie M, Hahn A G. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.  Haematologica. 2001;  86 128-137
• 19 Pugh C W, O'Rourke J F, Nagao M, Gleadle J M, Ratcliffe P J. Activation of hypoxia-inducible factor-1: definition of regulatory domains within the α subunit.  J Biol Chem. 1997;  272 11205-11214
• 20 Round J M, Matthews Y, Jones D A. A quick, simple reliable histochemical method for ATPase used in human muscle preparations.  Histochem J. 1980;  12 707-710
• 21 Scoppetta C, Grassi F. Erythropoietin: a new tool for muscle disorders?.  Med Hypoth. 2004;  63 73-75
• 22 Semenza G L. HIF‐1 and human disease: one highly involved factor.  Genes Dev. 2000;  14 1983-1991
• 23 Urquilla P, Fong A, Oksanen S, Leigh S, Turtle E, Flippin L, Brenner M, Muthukrishnan E, Fourney P, Lin A, Yeowell D S, Malineaux C. Upregulation of endogenous EPO in healthy subjects by inhibition of HIF‐PHD (abstract SU-PO062).  J Am Soc Nephrol. 2004;  15 546A